– ISRAEL, Holon – Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors.

“I am delighted to welcome Jean-Pierre to Compugen’s Board,” said Paul Sekhri, Chairman of the Board. “I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen. We look forward to benefiting from his contribution as we continue building a robust pipeline of first-in-class immuno-oncology drugs addressing new drug targets discovered by our Company.”

“My professional life has been dedicated to advancing novel therapies in order to improve the lives of cancer patients, and I have been fortunate to be involved in the development and approval of multiple transformative oncology treatments,” said Jean-Pierre Bizzari, M.D. “Joining Compugen’s Board allows me the opportunity to continue this endeavor with a company whose innovative capabilities enable the computational discovery of new drug targets. I am thrilled to be part of the team and look forward to working with Compugen’s board of directors and management on translating its discovery capabilities into new cancer therapies for the benefit of patients worldwide.”

About Dr Jean-Pierre Bizzari

Dr. Jean-Pierre Bizzari is a world-renowned oncology expert who brings to Compugen over 35 years of broad experience in oncology drug development. Dr. Bizzari served as Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene’s clinical development and operations-statistics teams across the United States, Europe and Asia/Japan where he oversaw the development and approval of leading oncology products, including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis (formerly Rhône-Poulenc, Rhône-Poulenc Rorer and Aventis) where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Dr. Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). Dr. Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute, and the European Organization of Research and Treatment of Cancer and Chairman of the New Drug Advisory Committee. He also serves on the boards of Halozyme Therapeutics, Onxeo, Oxford BioTherapeutics, Pieris Pharmaceuticals, Nordic Nanovector and Transgene.  Dr. Bizzari received his medical degree from the Nice Medical School and has trained at the Pitié-Salpêtrière Hospital in Paris, The Ontario Institute for Cancer Research, and The McGill Rosalind and Morris Goodman Cancer Research Centre (formerly the McGill Cancer Center) in Montreal, Canada.

About Compugen

Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel with R&D facilities in Israel and South San Francisco, CA. Compugen’s ordinary shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

For more information, visit www.cgen.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.